Table 3.
Results obtained in the context of changes in microbiota described in the literature.
Ref. | Features of the Samples |
Main Findings | Outcomes Assessment |
---|---|---|---|
[88] | 181 subjects between 18 and 65 years old with chronic constipation |
There was an increase in beneficial bacteria (Lactiplantibacillus plantarum and Ruminococcus_B gnavus) and a decrease in pathogenic bacteria (Oscillospiraceae sp., Lachnospiraceae sp. and Herelleviridae). | Assessed by NMDS analyses of fecal samples |
[87] | 64 children between 3 and 17 years old with constipation | There was an increase in beneficial specific bifidobacteria, and their maintenance over time, increasing the stability of the microbiota. | Measured by the analysis of fecal samples |
[78] | 86 subjects between 20 and 65 years old with IBS |
There was an increase in stability with probiotic supplementation. | Assessed by a custom-made agilent microarray designed to cover the diversity of intestinal microbiota |
[79] | 55 subjects between 20 and 65 years old with IBS | Unexpectedly there was greater increase in Bifidobacterium spp. in the placebo group; however it may have been attributable to a competition between the administered species and others already detected at baseline in the placebo group, and with the supplementation a stability of the bacterial groups was observed. | Measured by real-time quantitative polymerase chain reaction |
[80] | 150 subjects between 18 and 65 years old with IBS-C | There was an increase in Lactobacillus spp. and Bifidobacterium spp. during treatment, stabilizing the gut microbiota. |
Fecal microbiology analysis was assessed by quantitative PRC |
[89] | 68 subjects with a mean age of 37 years old with functional bowel disorders | An increase in Bifidobacterium lactis was observed. | Fecal samples were collected and analyzed using DNA-base methods |
[81] | 30 subjects between 18 and 65 years old with IBS-C |
There was an increase in Lactobacillus acidophilus and Bifidobacterium animalis. | Fecal samples were collected and analyzed using real-time PCR |
[84] | 200 subjects between 18 and 65 years old with IBS-D | There was a reduction in Clostridium sensu stricto after treatment with Clostridium butyricum. | Stool samples were collected and analyzed using DNA-base methods |
[82] | 307 subjects between 18 and 70 years old with IBS-D | There was an enrichment of Lactiplantibacillus and Lactobacillus plantarum at the highest dose of the active group, as well as the maintenance of the stability and diversity of the microbiota. | Assessed by sample DNA isolation and quantification |
[83] | 42 subjects with a mean age of 46 years old with IBS | There was a decrease in Ruminococcus torques. | Measured by extraction and purification of DNA from fecal samples |
[85] | 109 subjects over 18 years old with celiac disease with IBS type-symptoms |
There was an increase in Lactobacillus, Lactococcus, Streptococcus, Staphylococcus and Bifidobacterium in the active group. | Measured by DNA and RNA extractions from fecal samples |
[91] | Extremely premature infants born at less than 1000 g birth weight and less than 29 weeks | There was an increase in the stability and interconnectivity of species supplemented in premature babies. | Assessed by strain-specific real-time PCR |
[86] | 40 subjects between 1 and 19 years old with celiac disease | There was an increase in Firmicutes, ensuring the stability of the microbiota with the maintenance of the Firmicutes/Bacteroidetes ratio. | Evaluated by DNA extraction from fecal samples |
[90] | 135 subjects between 20 and 67 years old with lactose intolerance and functional gastrointestinal symptoms |
There was an increase in Bifidobacterium and a decrease in Klebsiella, Serratia and Enterobacter in the active group. | Evaluated by RNA extraction from fecal samples |
[92] | 39 subjects with mean age of 49.8 with functional diarrhea |
There was an increase in Lactobacillales in the active group. | Assessed by DNA extraction from fecal samples |